stocks index  markets index x tweet share this bulletin get news bulletins by email bulletin ftse closes lower as uk tobacco stocks are routed » investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve pwhy mccain shot down obamacare repeal pchip stocks are cool again but reality is here pintel earnings have message for amd and nvidia ‘bring it on’ pamazon’s freespending ways hit earnings but don’t expect a shift to thrift pstarbucks’ teavana stores are the latest casualty at the mall pwagerebound story takes another hit after drab eci report pwhat is an ico ptrump’s sketch of new york city skyline auctioned off pwells fargo fda plan to lower nicotine could be opportunity for altria philip morris phealthcare fund managers say a spike in drugs and devices will produce big returns pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index x tweet share this bulletin get news bulletins by email bulletin ftse closes lower as uk tobacco stocks are routed » investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve pwhy mccain shot down obamacare repeal pchip stocks are cool again but reality is here pintel earnings have message for amd and nvidia ‘bring it on’ pamazon’s freespending ways hit earnings but don’t expect a shift to thrift pstarbucks’ teavana stores are the latest casualty at the mall pwagerebound story takes another hit after drab eci report pwhat is an ico ptrump’s sketch of new york city skyline auctioned off pwells fargo fda plan to lower nicotine could be opportunity for altria philip morris phealthcare fund managers say a spike in drugs and devices will produce big returns pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  overview  evoke pharma home  investor relations  overview evokepharma overview evoke pharma inc nasdaq evok is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal or gi disorders and diseases the company is developing gimoti™ a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus diabetic gastroparesis is a gi disorder afflicting millions of sufferers worldwide in which the stomach takes too long or fails to empty its contents resulting in serious digestive system symptoms metoclopramide is the only product currently approved in the united states to treat gastroparesis and is currently available only in oral and intravenous forms gimoti is a novel formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration to avoid gastric absorption issues intra  mo  mo  yr press releases may   evoke pharma enters agreement with rho to submit nda for gimoti may   evoke pharma reports first quarter  results view all press releases events may   at  pm et evoke pharma first quarter  conference call mar   at  pm et evoke pharma fourth quarter  conference call view all events presentations and posters evoke pharma investor presentation evoke pharma presentation at ddw conference may   evoke pharma to present at rodman  renshaw th annual global investment conference overview  evoke pharma home  investor relations  overview evokepharma overview evoke pharma inc nasdaq evok is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal or gi disorders and diseases the company is developing gimoti™ a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus diabetic gastroparesis is a gi disorder afflicting millions of sufferers worldwide in which the stomach takes too long or fails to empty its contents resulting in serious digestive system symptoms metoclopramide is the only product currently approved in the united states to treat gastroparesis and is currently available only in oral and intravenous forms gimoti is a novel formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration to avoid gastric absorption issues intra  mo  mo  yr press releases may   evoke pharma enters agreement with rho to submit nda for gimoti may   evoke pharma reports first quarter  results view all press releases events may   at  pm et evoke pharma first quarter  conference call mar   at  pm et evoke pharma fourth quarter  conference call view all events presentations and posters evoke pharma investor presentation evoke pharma presentation at ddw conference may   evoke pharma to present at rodman  renshaw th annual global investment conference evok stock price  evoke pharma inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin ftse closes lower as uk tobacco stocks are routed bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  expe  col  gt  fls  mo  sbux  latest newsall times eastern p where healthcare reform goes after failure to repeal and replace obamacare p sp  down  points or  at  p dow industrials down  points at  p breaking nasdaq pares losses down  points at  p updated ftse  closes sharply lower in tobaccoled stock rout p here’s how much you should spend on a yoga mat and why you should always use your own p updated how advisers can fight the ‘crisis of trust’ in financial services p updated how venezuela chaos could spark oil rally opec has failed to achieve p why mccain shot down obamacare repeal p updated chip stocks are cool again but reality is here to be replaced home investing quotes stocks united states evok overview compare quotes stock screener earnings calendar sectors nasdaq evok us nasdaq join td ameritrade find a broker evoke pharma inc watchlist createevokalert open last updated jul    pm edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones evoke pharmas stock soars after fda exempts gimoti from hf validation feb   at  am et by tomi kilgore evoke pharmas stock soars  premarket after positive fda product assessment feb   at  am et by tomi kilgore evoke pharma shares plunge  to pace nasdaq losers after drug trial disappoints jul   at  am et by tomi kilgore evoke pharma stock drops  after drugs latestage topline results miss primary endpoint jul   at  am et by emma court evoke pharma shares plummet  in premarket trade jul   at  am et by emma r court evoke pharma gastrointestival disease drug missed latestage endpoint jul   at  am et by emma r court no headlines available recent news other news press releases evoke pharmas evok ceo david gonyer on q  results  earnings call transcript evoke pharmas evok ceo david gonyer on q  results  earnings call transcript may   at  pm et on seeking alpha q evoke pharma inc q evoke pharma inc may   at  pm et on edgar online  edg  q k evoke pharma advancing gimoti nda filing possible by yearend shares ahead  apr   at  am et on seeking alpha premarket gainers as of  am apr   at  am et on seeking alpha evoke pharmas evok ceo david gonyer on q  results  earnings call transcript mar   at  pm et on seeking alpha k evoke pharma inc mar   at  pm et on edgar online  edg  q k insiderinsightscom daily round up  iep aapl sanw newm feb   at  am et on seeking alpha evoke pharma plan for accelerated review of nda for lead product candidate gimoti now more so shares ahead  feb   at  am et on seeking alpha laidlaw likes evoke sees  upside shares ahead  jan   at  pm et on seeking alpha evoke diabetic gastroparesis drug gimoti positive in phase iii jan   at  am et on zackscom evoke pharma mines data from failed latestage study of gimoti in diabetic gastroparesis valid treatment effect in subset of patients shares up  jan   at  am et on seeking alpha biotech forum daily digest santa claus rally on horizon spotlight on stemline therapeutics dec   at  pm et on seeking alpha company news for december   dec   at  am et on zackscom a trump presidency may be good for biotech dec   at  pm et on gurufocuscom biggest movers in manufacturing stocks now – evok apvo elgx hznp dec   at  am et on investorplacecom evoke pharma jumps  on improved prospects for gimoti dec   at  am et on seeking alpha evoke pharmas evok ceo dave gonyer on q  results  earnings call transcript nov   at  pm et on seeking alpha notable earnings after wednesday’s close nov   at  pm et on seeking alpha hottest manufacturing stocks now – catb aegr bspm qlti sep   at  am et on investorplacecom biggest movers in manufacturing stocks now – spu cccl cfrx athx sep   at  am et on investorplacecom generic drugs stocks on investors radar  catalyst pharma lannett evoke pharma and galectin therapeutics generic drugs stocks on investors radar  catalyst pharma lannett evoke pharma and galectin therapeutics jun   at  am et on pr newswire  prf evoke pharma enters agreement with rho to submit nda for gimoti evoke pharma enters agreement with rho to submit nda for gimoti may   at  am et on globenewswire evoke pharma reports first quarter  results evoke pharma reports first quarter  results may   at  pm et on globenewswire investor network evoke pharma inc to host earnings call investor network evoke pharma inc to host earnings call may   at  pm et on accesswire evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  may   at  am et on globenewswire evoke pharma schedules conference call and webcast for first quarter  financial results evoke pharma schedules conference call and webcast for first quarter  financial results may   at  am et on globenewswire how these generic drugs stocks are faring  evoke pharma neurocrine biosciences lannett and catalent apr   at  am et on pr newswire  prf evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial apr   at  am et on globenewswire positive type a meeting with fda confirms acceptability of evoke pharmas proposed comparative exposure pk trial for gimoti nda apr   at  am et on globenewswire generic drugs stocks on investors radar  mylan allergan horizon pharma and evoke pharma mar   at  am et on pr newswire  prf evoke pharmas phase  results for gimoti accepted as latebreaker for presentation at digestive disease week  mar   at  am et on globenewswire evoke pharma reports fourth quarter and full year  results mar   at  pm et on globenewswire evoke pharma schedules webcast and conference call for fourth quarter and fullyear  financial results mar   at  am et on globenewswire evoke pharma announces full exercise of underwriters option to purchase additional shares mar   at  am et on globenewswire biotech industry poised for a breakout in  todays reports on evoke pharma and novavax feb   at  am et on accesswire evoke pharma announces pricing of public offering of common stock feb   at  am et on globenewswire evoke pharma announces proposed public offering of common stock feb   at  pm et on globenewswire fda exempts evoke from requirement for human factor validation study feb   at  am et on globenewswire how these generic drugs stocks are faring  neurocrine biosciences evoke pharma scynexis and eagle pharma feb   at  am et on pr newswire  prf biotech acquisitions on the rise in  latest reports on calithera biosciences and evoke pharma jan   at  am et on accesswire evoke pharma inc evoke pharma inc is a pharmaceutical company which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases it develops evk for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women the company was founded by matthew j donofrio cam l garner scott l glenn and david a gonyer on january   and is headquartered in solana beach ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top downgrades jul   at  am et on benzingacom evoke pharma plunges  prompting brean to downgrade the stock from buy jul   at  am et on benzingacom benzingas top initiations mar   at  am et on benzingacom competitors name chg  market cap progenics pharmaceuticals inc  m sucampo pharmaceuticals inc cl a  m ironwood pharmaceuticals inc cl a  b synergy pharmaceuticals inc  m ocera therapeutics inc  m competitor data provided by partner content trending tickers powered by aks  x  dvax  baba  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience evoknasdaq cm stock quote  evoke pharma inc  bloomberg markets error could not add to watchlist x  watchlist evoke pharma inc evokus nasdaq cm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  iridex announces appointment of ann rhoads to its board of directors  evoke pharma enters agreement with rho to submit nda for gimoti  evoke pharma reports first quarter  results  evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week   evoke pharma schedules conference call and webcast for first quarter  financial results  evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial  positive type a meeting with fda confirms acceptability of evoke pharma’s proposed comparative exposure pk trial for gimoti n  galenica sante expects to price first swiss ipo of the year  evoke pharma’s phase  results for gimoti accepted as latebreaker for presentation at digestive disease week   evoke pharma reports fourth quarter and full year  results there are currently no press releases for this ticker please check back later profile evoke pharma inc develops manufactures and markets pharmaceutical products the company offers a gastrointestinal product for the treatment of patients with diabetic gastroparesis for patients suffering from gastrointestinal diseases and disorders evoke pharma conducts its business in the united states address  lomas santa fe drivesuite solana beach ca united states phone  website wwwevokepharmacom executives board members david a gonyer dave presidentceocofounder marilyn r carlson chief medical officer matthew j donofrio matt exec vpchief business ofcr show more stockscountryunited states index  markets index x tweet share this bulletin get news bulletins by email bulletin ftse closes lower as uk tobacco stocks are routed » investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve pwhy mccain shot down obamacare repeal pchip stocks are cool again but reality is here pintel earnings have message for amd and nvidia ‘bring it on’ pamazon’s freespending ways hit earnings but don’t expect a shift to thrift pstarbucks’ teavana stores are the latest casualty at the mall pwagerebound story takes another hit after drab eci report pwhat is an ico ptrump’s sketch of new york city skyline auctioned off pwells fargo fda plan to lower nicotine could be opportunity for altria philip morris phealthcare fund managers say a spike in drugs and devices will produce big returns pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  overview  evoke pharma home  investor relations  overview evokepharma overview evoke pharma inc nasdaq evok is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal or gi disorders and diseases the company is developing gimoti™ a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus diabetic gastroparesis is a gi disorder afflicting millions of sufferers worldwide in which the stomach takes too long or fails to empty its contents resulting in serious digestive system symptoms metoclopramide is the only product currently approved in the united states to treat gastroparesis and is currently available only in oral and intravenous forms gimoti is a novel formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration to avoid gastric absorption issues intra  mo  mo  yr press releases may   evoke pharma enters agreement with rho to submit nda for gimoti may   evoke pharma reports first quarter  results view all press releases events may   at  pm et evoke pharma first quarter  conference call mar   at  pm et evoke pharma fourth quarter  conference call view all events presentations and posters evoke pharma investor presentation evoke pharma presentation at ddw conference may   evoke pharma to present at rodman  renshaw th annual global investment conference microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft overview  evoke pharma home  investor relations  overview evokepharma overview evoke pharma inc nasdaq evok is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal or gi disorders and diseases the company is developing gimoti™ a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus diabetic gastroparesis is a gi disorder afflicting millions of sufferers worldwide in which the stomach takes too long or fails to empty its contents resulting in serious digestive system symptoms metoclopramide is the only product currently approved in the united states to treat gastroparesis and is currently available only in oral and intravenous forms gimoti is a novel formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration to avoid gastric absorption issues intra  mo  mo  yr press releases may   evoke pharma enters agreement with rho to submit nda for gimoti may   evoke pharma reports first quarter  results view all press releases events may   at  pm et evoke pharma first quarter  conference call mar   at  pm et evoke pharma fourth quarter  conference call view all events presentations and posters evoke pharma investor presentation evoke pharma presentation at ddw conference may   evoke pharma to present at rodman  renshaw th annual global investment conference historic stock lookup  evoke pharma home  investor relations  historic stock lookup evokepharma historic stock lookup adjusted historic prices for the week of july   date open high low close volume jul        jul        jul        jul        historic month january february march april may june july august september october november december historic day  historic year  lookup the historical stock information provided is for informational purposes only and is not intended for trading purposes the historical stock information is provided by mergent a third party service and evoke pharma does not maintain or provide information directly to this service prices display splitadjusted cost basis per share on that date evok stock price  evoke pharma inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin ftse closes lower as uk tobacco stocks are routed bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  expe  col  gt  fls  mo  sbux  latest newsall times eastern p where healthcare reform goes after failure to repeal and replace obamacare p sp  down  points or  at  p dow industrials down  points at  p breaking nasdaq pares losses down  points at  p updated ftse  closes sharply lower in tobaccoled stock rout p here’s how much you should spend on a yoga mat and why you should always use your own p updated how advisers can fight the ‘crisis of trust’ in financial services p updated how venezuela chaos could spark oil rally opec has failed to achieve p why mccain shot down obamacare repeal p updated chip stocks are cool again but reality is here to be replaced home investing quotes stocks united states evok overview compare quotes stock screener earnings calendar sectors nasdaq evok us nasdaq join td ameritrade find a broker evoke pharma inc watchlist createevokalert open last updated jul    pm edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones evoke pharmas stock soars after fda exempts gimoti from hf validation feb   at  am et by tomi kilgore evoke pharmas stock soars  premarket after positive fda product assessment feb   at  am et by tomi kilgore evoke pharma shares plunge  to pace nasdaq losers after drug trial disappoints jul   at  am et by tomi kilgore evoke pharma stock drops  after drugs latestage topline results miss primary endpoint jul   at  am et by emma court evoke pharma shares plummet  in premarket trade jul   at  am et by emma r court evoke pharma gastrointestival disease drug missed latestage endpoint jul   at  am et by emma r court no headlines available recent news other news press releases evoke pharmas evok ceo david gonyer on q  results  earnings call transcript evoke pharmas evok ceo david gonyer on q  results  earnings call transcript may   at  pm et on seeking alpha q evoke pharma inc q evoke pharma inc may   at  pm et on edgar online  edg  q k evoke pharma advancing gimoti nda filing possible by yearend shares ahead  apr   at  am et on seeking alpha premarket gainers as of  am apr   at  am et on seeking alpha evoke pharmas evok ceo david gonyer on q  results  earnings call transcript mar   at  pm et on seeking alpha k evoke pharma inc mar   at  pm et on edgar online  edg  q k insiderinsightscom daily round up  iep aapl sanw newm feb   at  am et on seeking alpha evoke pharma plan for accelerated review of nda for lead product candidate gimoti now more so shares ahead  feb   at  am et on seeking alpha laidlaw likes evoke sees  upside shares ahead  jan   at  pm et on seeking alpha evoke diabetic gastroparesis drug gimoti positive in phase iii jan   at  am et on zackscom evoke pharma mines data from failed latestage study of gimoti in diabetic gastroparesis valid treatment effect in subset of patients shares up  jan   at  am et on seeking alpha biotech forum daily digest santa claus rally on horizon spotlight on stemline therapeutics dec   at  pm et on seeking alpha company news for december   dec   at  am et on zackscom a trump presidency may be good for biotech dec   at  pm et on gurufocuscom biggest movers in manufacturing stocks now – evok apvo elgx hznp dec   at  am et on investorplacecom evoke pharma jumps  on improved prospects for gimoti dec   at  am et on seeking alpha evoke pharmas evok ceo dave gonyer on q  results  earnings call transcript nov   at  pm et on seeking alpha notable earnings after wednesday’s close nov   at  pm et on seeking alpha hottest manufacturing stocks now – catb aegr bspm qlti sep   at  am et on investorplacecom biggest movers in manufacturing stocks now – spu cccl cfrx athx sep   at  am et on investorplacecom generic drugs stocks on investors radar  catalyst pharma lannett evoke pharma and galectin therapeutics generic drugs stocks on investors radar  catalyst pharma lannett evoke pharma and galectin therapeutics jun   at  am et on pr newswire  prf evoke pharma enters agreement with rho to submit nda for gimoti evoke pharma enters agreement with rho to submit nda for gimoti may   at  am et on globenewswire evoke pharma reports first quarter  results evoke pharma reports first quarter  results may   at  pm et on globenewswire investor network evoke pharma inc to host earnings call investor network evoke pharma inc to host earnings call may   at  pm et on accesswire evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  may   at  am et on globenewswire evoke pharma schedules conference call and webcast for first quarter  financial results evoke pharma schedules conference call and webcast for first quarter  financial results may   at  am et on globenewswire how these generic drugs stocks are faring  evoke pharma neurocrine biosciences lannett and catalent apr   at  am et on pr newswire  prf evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial apr   at  am et on globenewswire positive type a meeting with fda confirms acceptability of evoke pharmas proposed comparative exposure pk trial for gimoti nda apr   at  am et on globenewswire generic drugs stocks on investors radar  mylan allergan horizon pharma and evoke pharma mar   at  am et on pr newswire  prf evoke pharmas phase  results for gimoti accepted as latebreaker for presentation at digestive disease week  mar   at  am et on globenewswire evoke pharma reports fourth quarter and full year  results mar   at  pm et on globenewswire evoke pharma schedules webcast and conference call for fourth quarter and fullyear  financial results mar   at  am et on globenewswire evoke pharma announces full exercise of underwriters option to purchase additional shares mar   at  am et on globenewswire biotech industry poised for a breakout in  todays reports on evoke pharma and novavax feb   at  am et on accesswire evoke pharma announces pricing of public offering of common stock feb   at  am et on globenewswire evoke pharma announces proposed public offering of common stock feb   at  pm et on globenewswire fda exempts evoke from requirement for human factor validation study feb   at  am et on globenewswire how these generic drugs stocks are faring  neurocrine biosciences evoke pharma scynexis and eagle pharma feb   at  am et on pr newswire  prf biotech acquisitions on the rise in  latest reports on calithera biosciences and evoke pharma jan   at  am et on accesswire evoke pharma inc evoke pharma inc is a pharmaceutical company which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases it develops evk for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women the company was founded by matthew j donofrio cam l garner scott l glenn and david a gonyer on january   and is headquartered in solana beach ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top downgrades jul   at  am et on benzingacom evoke pharma plunges  prompting brean to downgrade the stock from buy jul   at  am et on benzingacom benzingas top initiations mar   at  am et on benzingacom competitors name chg  market cap progenics pharmaceuticals inc  m sucampo pharmaceuticals inc cl a  m ironwood pharmaceuticals inc cl a  b synergy pharmaceuticals inc  m ocera therapeutics inc  m competitor data provided by partner content trending tickers powered by aks  x  dvax  baba  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience evok key statistics  evoke pharma inc financial ratios  marketwatch x tweet share this bulletin get news bulletins by email bulletin ftse closes lower as uk tobacco stocks are routed » investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close evoke pharma inc nasdaq evok go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus evoke pharma inc market open  real time quotes jul    pm evok quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description evoke pharma inc is a pharmaceutical company which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases it develops evk for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women the company was founded by matth evoke pharma inc is a pharmaceutical company which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases it develops evk for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women the company was founded by matthew j donofrio cam l garner scott l glenn and david a gonyer on january   and is headquartered in solana beach ca valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr david a gonyer   president ceo  class i director dr marilyn r carlson   chief medical officer mr matthew j donofrio   secretary treasurer chief business officer  evp mr cam l garner   chairman dr kenneth j widder   independent director insider actions – purchase – sale  – number of transactions  date name shares transaction value  david a gonyer president and ceo director      matthew j donofrio exec vp chief bus officer      marilyn r carlson chief medical officer      latterell venture partners director    acquisition at  per share   latterell venture partners director    acquisition at  per share   latterell venture partners director    acquisition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share   domain associates llc    disposition at  per share  newslatestcompanyusevok marketwatch news on evok evoke pharmas stock soars after fda exempts gimoti from hf validation  am feb    tomi kilgore evoke pharmas stock soars  premarket after positive fda product assessment  am feb    tomi kilgore evoke pharma shares plunge  to pace nasdaq losers after drug trial disappoints  am july    tomi kilgore evoke pharma stock drops  after drugs latestage topline results miss primary endpoint  am july    emma court evoke pharma shares plummet  in premarket trade  am july    emma r court evoke pharma gastrointestival disease drug missed latestage endpoint  am july    emma r court newsnonmarketwatchcompanyusevok other news on evok evoke pharmas evok ceo david gonyer on q  results  earnings call transcript  pm may    seeking alpha q evoke pharma inc  pm may    edgar online  edg  q k evoke pharma advancing gimoti nda filing possible by yearend shares ahead   am april    seeking alpha premarket gainers as of  am  am april    seeking alpha evoke pharmas evok ceo david gonyer on q  results  earnings call transcript  pm march    seeking alpha k evoke pharma inc  pm march    edgar online  edg  q k insiderinsightscom daily round up  iep aapl sanw newm  am feb    seeking alpha evoke pharma plan for accelerated review of nda for lead product candidate gimoti now more so shares ahead   pm feb    seeking alpha laidlaw likes evoke sees  upside shares ahead   pm jan    seeking alpha evoke diabetic gastroparesis drug gimoti positive in phase iii  am jan    zackscom evoke pharma mines data from failed latestage study of gimoti in diabetic gastroparesis valid treatment effect in subset of patients shares up   am jan    seeking alpha biotech forum daily digest santa claus rally on horizon spotlight on stemline therapeutics  pm dec    seeking alpha company news for december    am dec    zackscom a trump presidency may be good for biotech  pm dec    gurufocuscom biggest movers in manufacturing stocks now – evok apvo elgx hznp  am dec    investorplacecom evoke pharma jumps  on improved prospects for gimoti  am dec    seeking alpha evoke pharmas evok ceo dave gonyer on q  results  earnings call transcript  pm nov    seeking alpha notable earnings after wednesday’s close  pm nov    seeking alpha hottest manufacturing stocks now – catb aegr bspm qlti  am sept    investorplacecom biggest movers in manufacturing stocks now – spu cccl cfrx athx  am sept    investorplacecom loading more headlines at a glance evoke pharma inc  stevens avenue suite  solana beach california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for evok newspressreleasecompanyusevok press releases on evok generic drugs stocks on investors radar  catalyst pharma lannett evoke pharma and galectin therapeutics  am june    pr newswire  prf evoke pharma enters agreement with rho to submit nda for gimoti  am may    globenewswire evoke pharma reports first quarter  results  pm may    globenewswire investor network evoke pharma inc to host earnings call  pm may    accesswire evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week   am may    globenewswire evoke pharma schedules conference call and webcast for first quarter  financial results  am may    globenewswire how these generic drugs stocks are faring  evoke pharma neurocrine biosciences lannett and catalent  am april    pr newswire  prf evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial  am april    globenewswire positive type a meeting with fda confirms acceptability of evoke pharmas proposed comparative exposure pk trial for gimoti nda  am april    globenewswire generic drugs stocks on investors radar  mylan allergan horizon pharma and evoke pharma  am march    pr newswire  prf evoke pharmas phase  results for gimoti accepted as latebreaker for presentation at digestive disease week   am march    globenewswire evoke pharma reports fourth quarter and full year  results  pm march    globenewswire evoke pharma schedules webcast and conference call for fourth quarter and fullyear  financial results  am march    globenewswire evoke pharma announces full exercise of underwriters option to purchase additional shares  am march    globenewswire biotech industry poised for a breakout in  todays reports on evoke pharma and novavax  am feb    accesswire evoke pharma announces pricing of public offering of common stock  am feb    globenewswire evoke pharma announces proposed public offering of common stock  pm feb    globenewswire fda exempts evoke from requirement for human factor validation study  am feb    globenewswire how these generic drugs stocks are faring  neurocrine biosciences evoke pharma scynexis and eagle pharma  am feb    pr newswire  prf biotech acquisitions on the rise in  latest reports on calithera biosciences and evoke pharma  am jan    accesswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve pwhy mccain shot down obamacare repeal pchip stocks are cool again but reality is here pintel earnings have message for amd and nvidia ‘bring it on’ pamazon’s freespending ways hit earnings but don’t expect a shift to thrift pstarbucks’ teavana stores are the latest casualty at the mall pwagerebound story takes another hit after drab eci report pwhat is an ico ptrump’s sketch of new york city skyline auctioned off pwells fargo fda plan to lower nicotine could be opportunity for altria philip morris phealthcare fund managers say a spike in drugs and devices will produce big returns pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  evok stock quote  evoke pharma inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  evok evoke pharma inc common stock quote  summary data       get evok alerts delayed  data as of jul    et    find a broker to begin trading evok now exchangenasdaq industry health care community rating view    evok real time evok     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock       year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple ne forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec we are a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal or gi disorders and diseases we are developing gimoti an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women diabetic gastroparesis is a gi disorder afflicting millions of patients worldwide in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms and other complications metoclopramide is the only product currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic gastroparesis and is currently available only in oral tablet and injection dose forms gimoti is a novel formulation of this drug designed to provide systemic delivery of metoclopramide through nasal spray administration   more    risk grade where does evok fit in the risk graph news for evok investor network evoke pharma inc to host earnings call   pm  accesswire monday  insider buying report evok avp   am  bnk invest insiderinsightscom daily round up  iep aapl sanw newm   am  seeking alpha close update wall street sets records for fifth straight day as trump talks taxes   pm  mt newswires health care sector update for  trupevokclsn   pm  mt newswires  subscribe more evok news  commentary read evok press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex press releases  evoke pharma home  investor relations  press releases evokepharma press releases filter releases year all years      sort by date descending date ascending update   press releases date title and summary view may   evoke pharma enters agreement with rho to submit nda for gimoti solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has entered into an agreement with rho inc a regulatory consulting and contract research organization cro rho will  html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results confirmed fda acceptability of comparative exposure pharmacokinetic pk study design and agreement on related cmc data package elements for gimoti™ new drug application ndapartnered with spaulding clinical research to complete pk study in second half of received fda agreement that a human factors html pdf add to briefcase file is in briefcase may   evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from its phase  trial of gimoti™ its patented nasal delivery of metoclopramide for the relief of symptoms associa html pdf add to briefcase file is in briefcase may   evoke pharma schedules conference call and webcast for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the company will release financial results for the first quarter ended march   on monday may   after the market html pdf add to briefcase file is in briefcase apr   evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company has reached an agreement to work in partnership with spaulding clinical research for its planned comparative e html pdf add to briefcase file is in briefcase apr   positive type a meeting with fda confirms acceptability of evoke pharmas proposed comparative exposure pk trial for gimoti nda solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company recently completed a positive type a meeting with the us food and drug administration fda to finalize the  html pdf add to briefcase file is in briefcase mar   evoke pharmas phase  results for gimoti accepted as latebreaker for presentation at digestive disease week  solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the companys abstract detailing compelling phase  trial data for gimoti™ metoclopramide nasal spray for the relief  html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and full year  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced its financial results for the fourth quarter and full year ended december   dave gonyer rph pres html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and fullyear  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the company will release financial results for the fourth quarter and full year ended december   on wednesday march  html pdf add to briefcase file is in briefcase mar   evoke pharma announces full exercise of underwriters option to purchase additional shares solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the underwriter of its previously announced public offering of html pdf add to briefcase file is in briefcase feb   evoke pharma announces pricing of public offering of common stock solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that it has priced an underwritten public offering of  shares of its common stock at a price to the public of  per share  html pdf add to briefcase file is in briefcase feb   evoke pharma announces proposed public offering of common stock solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it intends to offer and sell shares of its common stock in a firm commitment underwritten public offering html pdf add to briefcase file is in briefcase feb   fda exempts evoke from requirement for human factor validation study solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced that it has received a letter from fda exempting its late stage product gimoti™ from a human factors hf validation study requ html pdf add to briefcase file is in briefcase jan   evoke pharma to attend  jpmorgan healthcare conference solana beach calif jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer and its chief business officer matt donofrio will be attending the html pdf add to briefcase file is in briefcase jan   evoke provides additional data demonstrating statistically significant benefit for gimoti in moderate to severe patients in phase  diabetic gastroparesis trial solana beach ca jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided additional data from the phase  trial of gimoti its nasal delivery of metoclopramide for the relief of symptoms associated with acu html pdf add to briefcase file is in briefcase dec   evoke receives positive nda submission guidance from us fda for gimoti solana beach calif dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced positive guidance from a recent second prenda new drug application meeting to discuss clinical data for inclusion in a b html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and  html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter  on wednesday november   after the close of the market html pdf add to briefcase file is in briefcase sep   evoke pharma announces positive nonclinical prenda meeting with fda for gimoti solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced that it has completed a pre‑new drug application nda meeting with the us food and drug administration fda r html pdf add to briefcase file is in briefcase sep   evoke pharma to present at rodman  renshaw th annual global investment conference solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer rph president and ceo will be presenting at the rodman  renshaw th annual global investment con html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced its financial results for the second quarter ended june   dave gonyer rph preside html pdf add to briefcase file is in briefcase aug   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter  on monday august   after the close of the market html pdf add to briefcase file is in briefcase aug   evoke pharma completes credit facility repayment solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced it has paid all of the outstanding amounts of indebtedness under its loan and security agreement the credit facil html pdf add to briefcase file is in briefcase jul   evoke pharma announces  million registered direct offering priced atthemarket solana beach calif july   globe newswire  evoke pharma inc nasdaqevok evoke pharma or the company today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately  million in a registered direct  html pdf add to briefcase file is in briefcase jul   evoke pharma receives conditional fda acceptance of proposed brand name for evk solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the us food and drug administration fda has conditionally accepted the proprietary brand name gimoti for the companys p html pdf add to briefcase file is in briefcase jul   evoke pharma announces  million atthemarket offering solana beach calif july   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common s html pdf add to briefcase file is in briefcase jul   evoke pharma reports topline results from evk phase  clinical trial solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced topline results from its phase  clinical trial of evk in female patients with symptomatic diabetic gastroparesis in this stud html pdf add to briefcase file is in briefcase jul   evoke advances commercial preparations for evk with inventiv agreement solana beach calif july   globe newswire  evoke pharma inc nasdaqevok today announced that it has entered into a master service agreement with inventiv commercial services llc inventiv in connection with evokes preparation for commercial activities for evk its lead product candidate for the treatmen html pdf add to briefcase file is in briefcase jul   evoke advances commercial preparations for evk with inventiv agreement solana beach calif july   globe newswire  evoke pharma inc nasdaqevok today announced that it has entered into a master service agreement with inventiv commercial services llc inventiv in connection with evokes preparation for commercial activities for evk its lead product candidate for the treatment of diabetic gast html pdf add to briefcase file is in briefcase jun   evoke completes phase  clinical trial of evk in women with symptoms associated with diabetic gastroparesis solana beach calif june   globe newswire  evoke pharma inc nasdaqevok today announced that the last subject completed treatment in its pivotal phase  study for evk the companys patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic  html pdf add to briefcase file is in briefcase may   evoke pharma presents data from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from its successful thorough electrocardiogram ecg study of evk its patented nasal delivery formulation of metoclop html pdf add to briefcase file is in briefcase may   evoke enters exclusive commercial supply agreement for active pharmaceutical ingredient in evk solana beach calif may   globe newswire  evoke pharma inc nasdaqevok today announced that it has signed an exclusive commercial supply agreement with cosma spa for the active pharmaceutical ingredient api in its product candidate evk evk is the companys novel nasal spray for delivery of metoclo html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated the start  html pdf add to briefcase file is in briefcase may   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter  on wednesday may   after the close of the market html pdf add to briefcase file is in briefcase may   evoke announces timing of phase  results from its recently fully enrolled pivotal clinical trial of evk solana beach calif may   globe newswire  evoke pharma inc nasdaqevok today announced that it expects to provide top line data results from its pivotal phase  clinical trial of evk in women with symptoms associated with diabetic gastroparesis early in the third quarter of  the study was designed to en html pdf add to briefcase file is in briefcase apr   evoke successfully completes phase  clinical trial enrollment of evk in women with symptoms associated with diabetic gastroparesis solana beach calif april   globe newswire  evoke pharma inc nasdaqevok today announced that it has successfully completed patient enrollment in its pivotal phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurren html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president  html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and year end  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter and full year  on thursday march   after the close  html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and year end  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter and full year  on thursday march   after the close of the market  html pdf add to briefcase file is in briefcase mar   evoke accelerates new drug application process by engaging regulatory experts solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has engaged regulatory professionals inc rpi to provide additional personnel and expertise to the company in connection with the pr html pdf add to briefcase file is in briefcase mar   evoke nears completion of phase  clinical trial enrollment and secures extension to credit facility solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on enrollment of its ongoing phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide html pdf add to briefcase file is in briefcase mar   evoke nears completion of phase  clinical trial enrollment and secures extension to credit facility solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on enrollment of its ongoing phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide for the relief of html pdf add to briefcase file is in briefcase feb   evoke pharma to present results from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys successful thorough electrocardiogram ecg study of evk its metoclopramide nasal spray product candidate w html pdf add to briefcase file is in briefcase feb   evoke pharma to present results from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys successful thorough electrocardiogram ecg study of evk its metoclopramide nasal spray product candidate were acc html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated this was an exciting quar html pdf add to briefcase file is in briefcase nov   evoke to participate in the brean capital  life sciences summit solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer rph president and ceo will be participating in the brean capital  life sciences summit on monday november   at the mil html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on thursday november   after the close of the market evoke will hol html pdf add to briefcase file is in briefcase oct   evoke pharma strengthens financial position solana beach calif oct   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the amendment of its loan and security agreement with square  bank the credit facility to extend the interestonly payment term for an additional  html pdf add to briefcase file is in briefcase sep   evoke reaches study enrollment milestone associated with credit facility solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company has reached a key milestone under its  million loan and security agreement the credit facility with square  bank square  a html pdf add to briefcase file is in briefcase sep   us food and drug administrations fda draft guidance is consistent with evokes current phase  study design and endpoint for evk solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its phase  clinical trial design for evk metoclopramide nasal spray is consistent with the fdas recommendations in the recently released  html pdf add to briefcase file is in briefcase aug   evoke receives favorable response from us food and drug administration regarding pediatric study plan for evk solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the receipt of a letter from the us food and drug administration fda indicating the agencys concurrence with the companys proposed pediatric stud html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results enrolled  total subjects in phase  clinical trial through end of july recent fda draft guidance of advice on gastroparesis mirrors evokes phase  clinical trial protocol design solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for  html pdf add to briefcase file is in briefcase jul   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter of  on thursday august   after the close of the market evoke will html pdf add to briefcase file is in briefcase jul   evoke pharma to present at cantor fitzgerald inaugural healthcare conference solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on wednesday july   at  am et at the cantor fitzgerald inaugural healthcare conference the conference is being held on j html pdf add to briefcase file is in briefcase jun   evoke pharma announces publication of clinical data demonstrating evk significantly improves symptoms in women with diabetic gastroparesis solana beach calif june   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that previously disclosed results from its phase b clinical trial evaluating evk its patented intranasal delivery formulation of metoclopramide f html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated we continue to make important  html pdf add to briefcase file is in briefcase apr   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter of  on thursday may   after the close of the market evoke will hold a html pdf add to briefcase file is in briefcase apr   evoke pharma achieves significant manufacturing milestone with successful completion of commercial scale production of evk solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has completed the production of a commercial scale lot of evk as required by the us food and drug administration fda with the html pdf add to briefcase file is in briefcase apr   evoke pharma granted european union formulation patent for evk solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the european patent office has granted the company european union eu patent no  for its lead product candidate evk this patent is  html pdf add to briefcase file is in briefcase mar   evoke pharma to present at the th annual roth conference solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on wednesday march   at am pt at the th annual roth conference the conference is being held march  at the ritzc html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president and ceo stated by achieving two sig html pdf add to briefcase file is in briefcase feb   evoke pharma schedules webcast and conference call for fourth quarter  financial results solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter of  on wednesday march   after the close of the market evoke will  html pdf add to briefcase file is in briefcase feb   evoke pharma outlines progress on clinical program solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on its clinical program for evk its novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabet html pdf add to briefcase file is in briefcase dec   evoke pharmas evk showed no qt prolongation in thorough ecg tqt study solana beach calif dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced results from an electrocardiogram ecg study that assessed the potential of metoclopramide nasal spray evk to increase the cardiac qt and correct html pdf add to briefcase file is in briefcase nov   evoke pharma to present at ld micro conference solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on thursday december   at am pt at the ld micro main event vii conference the conference is being held december   html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated during the third quarter html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on thursday november   after the close of the market evoke will html pdf add to briefcase file is in briefcase sep   evoke pharma announces the completion of enrollment in its thorough ecg study for evk solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has completed enrollment in its thorough ecg qt study of evk the companys lead product candidate evk is currently in a phase  cli html pdf add to briefcase file is in briefcase sep   evoke pharma to present at the aegis capital corp  healthcare  technology conference solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer ceo will present a corporate overview at the aegis capital corp  healthcare  technology conference being held september  html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the second quarter ended june   dave gonyer rph president and ceo stated we continue to execute on the html pdf add to briefcase file is in briefcase aug   evoke pharma announces initiation of a thorough ecg qt study for evk solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the initiation of its thorough ecg qt study of the companys lead product candidate evk which is currently in a phase  clinical trial for the  html pdf add to briefcase file is in briefcase jul   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter of  on wednesday august   after the close of the market evoke wil html pdf add to briefcase file is in briefcase may   evoke pharma secures  million loan facility with square  bank solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has secured a  million term loan agreement with square  bank nasdaqsqbk in advance of this transaction evoke repaid the remaining bala html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated we have had a great start to  html pdf add to briefcase file is in briefcase may   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter of  on tuesday may   after the close of the market evoke will hold a html pdf add to briefcase file is in briefcase apr   evoke pharma announces that evk phase b results will be presented at digestive disease week  solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys phase b clinical trial of evk a novel intranasal formulation and delivery method of metoclopramide for diabetic fem html pdf add to briefcase file is in briefcase apr   evoke pharma initiates phase  clinical trial of evk for treatment of gastroparesis solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the initiation of its phase  clinical trial investigating the use of evk a novel metoclopramide nasal spray for the relief of symptoms associate html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president and ceo stated  was an exc html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter  financial results san diego march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter of  on tuesday march   after the close of the market evoke will hold a conf html pdf add to briefcase file is in briefcase mar   evoke pharma to present at th annual roth conference san diego march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer rph will be presenting at the th annual roth conference being held march   at the rit html pdf add to briefcase file is in briefcase jan   evoke pharma study reports positive results of metoclopramide nasal spray for gastroparesis in diabetics san diego jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the ma html pdf add to briefcase file is in briefcase jan   evoke pharma to present at biotech showcasetm  san diego jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer is scheduled to present at biotech showcase™  being held january   in san francisc html pdf add to briefcase file is in briefcase dec   evoke pharma strengthens executive team with appointments of chief medical officer and senior director of clinical operations san diego dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases announced today the appointment of marilyn r carlson dmd md rac as chief medical officer and wayne alves phd as senior director of clinical operations these two exe html pdf add to briefcase file is in briefcase nov   evoke pharma selects synteracthcr as contract research organization for phase  trial of evk for gastroparesis san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the selection of synteracthcr inc to serve as its primary contract research organization cro for its upcoming phase  clinical trial of evk evk is  html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated with the net proceeds of our initial html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on wednesday november   after the close of the market evoke will hold a co html pdf add to briefcase file is in briefcase oct   evoke pharma announces full exercise of underwriters overallotment option san diego oct   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the full exercise of the overallotment option granted to the representative of the underwriters to purchase an additional  shares of its common stock at a html pdf add to briefcase file is in briefcase sep   evoke pharma announces closing of initial public offering of  shares of common stock san diego sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the closing of its previously announced initial public offering of common stock the company sold a total of  shares of its common stock at an initial  html pdf add to briefcase file is in briefcase sep   evoke pharma announces pricing of initial public offering of  shares of common stock san diego ca september    evoke pharma inc a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the pricing of its initial public offering of  shares of its common stock at a public offering price of  per share the gross proceeds to evoke pharma from the init html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase evok  stock quote for evoke pharma inc  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices evoke pharma inc nasdaq evok us markets open adchoices  ▲   after hours     july    pm edt bats bzx realtime last price currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k k days range  wk range  market cap m dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news key executives for evoke pharma inc bloomberg  days ago elbit systems ltd nasdaqeslt reviewed by analysts desotoedgecom  hrs ago as itt educational services inc trades do analysts recommend you sell desotoedgecom  hrs ago marvell technology group ltd mrvl lowered to hold at zacks investment research fumbleboardcom  hrs ago marvell technology group mrvl getting somewhat favorable media coverage study shows nolopodrasdejardevercom  hrs ago rr partners lp has lowered foot locker fl position by  million evoke pharma evok’s sentiment is  the bibey post  hrs ago evoke pharma inc evok ukinvestingcom  days ago microsoft reports a big beat on earnings stock edges up fairydetoxorg  microsoft corporation q  earnings shares rise on strong results emfizzcom  evoke pharma inc nasdaqevok upgraded to “sell” by valuengine breeze  evoke pharma inc evok upgraded by valuengine to hold themarketsdailycom  bahl  gaynor inc boosted microsoft corporation msft position by  million techzolixcom  evoke pharma cash flow  quarterly nasdaqevok amigobullscom  iridex announces appointment of ann rhoads to its board of directors eyewiretodaycom  evoke pharma  benjamin f edwards  company has cut anadarko pete apc position evoke pharma evok had  bullish analysts  traders  analysts weekly ratings updates for anadarko petroleum corporation apc nyhetsbankeninfo  anadarko petroleum corporation nyseaeua experiences heavier than usual trading volume bulhufas  anadarko petroleum corporation nyseaeua trading volume significantly higher latribunadecanariascom  adchoices adchoices adchoices markets dow dow ▼    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support press releases  evoke pharma home  investor relations  press releases evokepharma press releases filter releases year all years      sort by date descending date ascending update   press releases date title and summary view may   evoke pharma enters agreement with rho to submit nda for gimoti solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has entered into an agreement with rho inc a regulatory consulting and contract research organization cro rho will  html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results confirmed fda acceptability of comparative exposure pharmacokinetic pk study design and agreement on related cmc data package elements for gimoti™ new drug application ndapartnered with spaulding clinical research to complete pk study in second half of received fda agreement that a human factors html pdf add to briefcase file is in briefcase may   evoke pharma presents gimoti efficacy and safety data from phase  trial as late breaker at digestive disease week  solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from its phase  trial of gimoti™ its patented nasal delivery of metoclopramide for the relief of symptoms associa html pdf add to briefcase file is in briefcase may   evoke pharma schedules conference call and webcast for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the company will release financial results for the first quarter ended march   on monday may   after the market html pdf add to briefcase file is in briefcase apr   evoke pharma announces collaboration with spaulding clinical research for the gimoti comparative exposure pharmacokinetic trial solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company has reached an agreement to work in partnership with spaulding clinical research for its planned comparative e html pdf add to briefcase file is in briefcase apr   positive type a meeting with fda confirms acceptability of evoke pharmas proposed comparative exposure pk trial for gimoti nda solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company recently completed a positive type a meeting with the us food and drug administration fda to finalize the  html pdf add to briefcase file is in briefcase mar   evoke pharmas phase  results for gimoti accepted as latebreaker for presentation at digestive disease week  solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the companys abstract detailing compelling phase  trial data for gimoti™ metoclopramide nasal spray for the relief  html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and full year  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced its financial results for the fourth quarter and full year ended december   dave gonyer rph pres html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and fullyear  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the company will release financial results for the fourth quarter and full year ended december   on wednesday march  html pdf add to briefcase file is in briefcase mar   evoke pharma announces full exercise of underwriters option to purchase additional shares solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that the underwriter of its previously announced public offering of html pdf add to briefcase file is in briefcase feb   evoke pharma announces pricing of public offering of common stock solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases announced today that it has priced an underwritten public offering of  shares of its common stock at a price to the public of  per share  html pdf add to briefcase file is in briefcase feb   evoke pharma announces proposed public offering of common stock solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it intends to offer and sell shares of its common stock in a firm commitment underwritten public offering html pdf add to briefcase file is in briefcase feb   fda exempts evoke from requirement for human factor validation study solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced that it has received a letter from fda exempting its late stage product gimoti™ from a human factors hf validation study requ html pdf add to briefcase file is in briefcase jan   evoke pharma to attend  jpmorgan healthcare conference solana beach calif jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer and its chief business officer matt donofrio will be attending the html pdf add to briefcase file is in briefcase jan   evoke provides additional data demonstrating statistically significant benefit for gimoti in moderate to severe patients in phase  diabetic gastroparesis trial solana beach ca jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided additional data from the phase  trial of gimoti its nasal delivery of metoclopramide for the relief of symptoms associated with acu html pdf add to briefcase file is in briefcase dec   evoke receives positive nda submission guidance from us fda for gimoti solana beach calif dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced positive guidance from a recent second prenda new drug application meeting to discuss clinical data for inclusion in a b html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and  html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter  on wednesday november   after the close of the market html pdf add to briefcase file is in briefcase sep   evoke pharma announces positive nonclinical prenda meeting with fda for gimoti solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced that it has completed a pre‑new drug application nda meeting with the us food and drug administration fda r html pdf add to briefcase file is in briefcase sep   evoke pharma to present at rodman  renshaw th annual global investment conference solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer rph president and ceo will be presenting at the rodman  renshaw th annual global investment con html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal diseases today announced its financial results for the second quarter ended june   dave gonyer rph preside html pdf add to briefcase file is in briefcase aug   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter  on monday august   after the close of the market html pdf add to briefcase file is in briefcase aug   evoke pharma completes credit facility repayment solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced it has paid all of the outstanding amounts of indebtedness under its loan and security agreement the credit facil html pdf add to briefcase file is in briefcase jul   evoke pharma announces  million registered direct offering priced atthemarket solana beach calif july   globe newswire  evoke pharma inc nasdaqevok evoke pharma or the company today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately  million in a registered direct  html pdf add to briefcase file is in briefcase jul   evoke pharma receives conditional fda acceptance of proposed brand name for evk solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the us food and drug administration fda has conditionally accepted the proprietary brand name gimoti for the companys p html pdf add to briefcase file is in briefcase jul   evoke pharma announces  million atthemarket offering solana beach calif july   globe newswire  evoke pharma inc nasdaqevok the company a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common s html pdf add to briefcase file is in briefcase jul   evoke pharma reports topline results from evk phase  clinical trial solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced topline results from its phase  clinical trial of evk in female patients with symptomatic diabetic gastroparesis in this stud html pdf add to briefcase file is in briefcase jul   evoke advances commercial preparations for evk with inventiv agreement solana beach calif july   globe newswire  evoke pharma inc nasdaqevok today announced that it has entered into a master service agreement with inventiv commercial services llc inventiv in connection with evokes preparation for commercial activities for evk its lead product candidate for the treatmen html pdf add to briefcase file is in briefcase jul   evoke advances commercial preparations for evk with inventiv agreement solana beach calif july   globe newswire  evoke pharma inc nasdaqevok today announced that it has entered into a master service agreement with inventiv commercial services llc inventiv in connection with evokes preparation for commercial activities for evk its lead product candidate for the treatment of diabetic gast html pdf add to briefcase file is in briefcase jun   evoke completes phase  clinical trial of evk in women with symptoms associated with diabetic gastroparesis solana beach calif june   globe newswire  evoke pharma inc nasdaqevok today announced that the last subject completed treatment in its pivotal phase  study for evk the companys patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic  html pdf add to briefcase file is in briefcase may   evoke pharma presents data from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from its successful thorough electrocardiogram ecg study of evk its patented nasal delivery formulation of metoclop html pdf add to briefcase file is in briefcase may   evoke enters exclusive commercial supply agreement for active pharmaceutical ingredient in evk solana beach calif may   globe newswire  evoke pharma inc nasdaqevok today announced that it has signed an exclusive commercial supply agreement with cosma spa for the active pharmaceutical ingredient api in its product candidate evk evk is the companys novel nasal spray for delivery of metoclo html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated the start  html pdf add to briefcase file is in briefcase may   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter  on wednesday may   after the close of the market html pdf add to briefcase file is in briefcase may   evoke announces timing of phase  results from its recently fully enrolled pivotal clinical trial of evk solana beach calif may   globe newswire  evoke pharma inc nasdaqevok today announced that it expects to provide top line data results from its pivotal phase  clinical trial of evk in women with symptoms associated with diabetic gastroparesis early in the third quarter of  the study was designed to en html pdf add to briefcase file is in briefcase apr   evoke successfully completes phase  clinical trial enrollment of evk in women with symptoms associated with diabetic gastroparesis solana beach calif april   globe newswire  evoke pharma inc nasdaqevok today announced that it has successfully completed patient enrollment in its pivotal phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurren html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president  html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and year end  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter and full year  on thursday march   after the close  html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter and year end  financial results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter and full year  on thursday march   after the close of the market  html pdf add to briefcase file is in briefcase mar   evoke accelerates new drug application process by engaging regulatory experts solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has engaged regulatory professionals inc rpi to provide additional personnel and expertise to the company in connection with the pr html pdf add to briefcase file is in briefcase mar   evoke nears completion of phase  clinical trial enrollment and secures extension to credit facility solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on enrollment of its ongoing phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide html pdf add to briefcase file is in briefcase mar   evoke nears completion of phase  clinical trial enrollment and secures extension to credit facility solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on enrollment of its ongoing phase  clinical trial of evk its patented nasal delivery formulation of metoclopramide for the relief of html pdf add to briefcase file is in briefcase feb   evoke pharma to present results from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys successful thorough electrocardiogram ecg study of evk its metoclopramide nasal spray product candidate w html pdf add to briefcase file is in briefcase feb   evoke pharma to present results from successful thorough ecg tqt study of evk at digestive disease week  solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys successful thorough electrocardiogram ecg study of evk its metoclopramide nasal spray product candidate were acc html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated this was an exciting quar html pdf add to briefcase file is in briefcase nov   evoke to participate in the brean capital  life sciences summit solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer rph president and ceo will be participating in the brean capital  life sciences summit on monday november   at the mil html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on thursday november   after the close of the market evoke will hol html pdf add to briefcase file is in briefcase oct   evoke pharma strengthens financial position solana beach calif oct   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the amendment of its loan and security agreement with square  bank the credit facility to extend the interestonly payment term for an additional  html pdf add to briefcase file is in briefcase sep   evoke reaches study enrollment milestone associated with credit facility solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the company has reached a key milestone under its  million loan and security agreement the credit facility with square  bank square  a html pdf add to briefcase file is in briefcase sep   us food and drug administrations fda draft guidance is consistent with evokes current phase  study design and endpoint for evk solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its phase  clinical trial design for evk metoclopramide nasal spray is consistent with the fdas recommendations in the recently released  html pdf add to briefcase file is in briefcase aug   evoke receives favorable response from us food and drug administration regarding pediatric study plan for evk solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the receipt of a letter from the us food and drug administration fda indicating the agencys concurrence with the companys proposed pediatric stud html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results enrolled  total subjects in phase  clinical trial through end of july recent fda draft guidance of advice on gastroparesis mirrors evokes phase  clinical trial protocol design solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for  html pdf add to briefcase file is in briefcase jul   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter of  on thursday august   after the close of the market evoke will html pdf add to briefcase file is in briefcase jul   evoke pharma to present at cantor fitzgerald inaugural healthcare conference solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on wednesday july   at  am et at the cantor fitzgerald inaugural healthcare conference the conference is being held on j html pdf add to briefcase file is in briefcase jun   evoke pharma announces publication of clinical data demonstrating evk significantly improves symptoms in women with diabetic gastroparesis solana beach calif june   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that previously disclosed results from its phase b clinical trial evaluating evk its patented intranasal delivery formulation of metoclopramide f html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated we continue to make important  html pdf add to briefcase file is in briefcase apr   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter of  on thursday may   after the close of the market evoke will hold a html pdf add to briefcase file is in briefcase apr   evoke pharma achieves significant manufacturing milestone with successful completion of commercial scale production of evk solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has completed the production of a commercial scale lot of evk as required by the us food and drug administration fda with the html pdf add to briefcase file is in briefcase apr   evoke pharma granted european union formulation patent for evk solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that the european patent office has granted the company european union eu patent no  for its lead product candidate evk this patent is  html pdf add to briefcase file is in briefcase mar   evoke pharma to present at the th annual roth conference solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on wednesday march   at am pt at the th annual roth conference the conference is being held march  at the ritzc html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president and ceo stated by achieving two sig html pdf add to briefcase file is in briefcase feb   evoke pharma schedules webcast and conference call for fourth quarter  financial results solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter of  on wednesday march   after the close of the market evoke will  html pdf add to briefcase file is in briefcase feb   evoke pharma outlines progress on clinical program solana beach calif feb   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today provided an update on its clinical program for evk its novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabet html pdf add to briefcase file is in briefcase dec   evoke pharmas evk showed no qt prolongation in thorough ecg tqt study solana beach calif dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced results from an electrocardiogram ecg study that assessed the potential of metoclopramide nasal spray evk to increase the cardiac qt and correct html pdf add to briefcase file is in briefcase nov   evoke pharma to present at ld micro conference solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases will host an investor presentation on thursday december   at am pt at the ld micro main event vii conference the conference is being held december   html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated during the third quarter html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results solana beach calif nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on thursday november   after the close of the market evoke will html pdf add to briefcase file is in briefcase sep   evoke pharma announces the completion of enrollment in its thorough ecg study for evk solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has completed enrollment in its thorough ecg qt study of evk the companys lead product candidate evk is currently in a phase  cli html pdf add to briefcase file is in briefcase sep   evoke pharma to present at the aegis capital corp  healthcare  technology conference solana beach calif sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that dave gonyer ceo will present a corporate overview at the aegis capital corp  healthcare  technology conference being held september  html pdf add to briefcase file is in briefcase aug   evoke pharma reports second quarter  results solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the second quarter ended june   dave gonyer rph president and ceo stated we continue to execute on the html pdf add to briefcase file is in briefcase aug   evoke pharma announces initiation of a thorough ecg qt study for evk solana beach calif aug   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the initiation of its thorough ecg qt study of the companys lead product candidate evk which is currently in a phase  clinical trial for the  html pdf add to briefcase file is in briefcase jul   evoke pharma schedules webcast and conference call for second quarter  financial results solana beach calif july   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the second quarter of  on wednesday august   after the close of the market evoke wil html pdf add to briefcase file is in briefcase may   evoke pharma secures  million loan facility with square  bank solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it has secured a  million term loan agreement with square  bank nasdaqsqbk in advance of this transaction evoke repaid the remaining bala html pdf add to briefcase file is in briefcase may   evoke pharma reports first quarter  results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the first quarter ended march   dave gonyer rph president and ceo stated we have had a great start to  html pdf add to briefcase file is in briefcase may   evoke pharma schedules webcast and conference call for first quarter  financial results solana beach calif may   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the first quarter of  on tuesday may   after the close of the market evoke will hold a html pdf add to briefcase file is in briefcase apr   evoke pharma announces that evk phase b results will be presented at digestive disease week  solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that data from the companys phase b clinical trial of evk a novel intranasal formulation and delivery method of metoclopramide for diabetic fem html pdf add to briefcase file is in briefcase apr   evoke pharma initiates phase  clinical trial of evk for treatment of gastroparesis solana beach calif april   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the initiation of its phase  clinical trial investigating the use of evk a novel metoclopramide nasal spray for the relief of symptoms associate html pdf add to briefcase file is in briefcase mar   evoke pharma reports fourth quarter and year end  results solana beach calif march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the fourth quarter and year ended december   dave gonyer rph president and ceo stated  was an exc html pdf add to briefcase file is in briefcase mar   evoke pharma schedules webcast and conference call for fourth quarter  financial results san diego march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the fourth quarter of  on tuesday march   after the close of the market evoke will hold a conf html pdf add to briefcase file is in briefcase mar   evoke pharma to present at th annual roth conference san diego march   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer rph will be presenting at the th annual roth conference being held march   at the rit html pdf add to briefcase file is in briefcase jan   evoke pharma study reports positive results of metoclopramide nasal spray for gastroparesis in diabetics san diego jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the ma html pdf add to briefcase file is in briefcase jan   evoke pharma to present at biotech showcasetm  san diego jan   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that its president and chief executive officer dave gonyer is scheduled to present at biotech showcase™  being held january   in san francisc html pdf add to briefcase file is in briefcase dec   evoke pharma strengthens executive team with appointments of chief medical officer and senior director of clinical operations san diego dec   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases announced today the appointment of marilyn r carlson dmd md rac as chief medical officer and wayne alves phd as senior director of clinical operations these two exe html pdf add to briefcase file is in briefcase nov   evoke pharma selects synteracthcr as contract research organization for phase  trial of evk for gastroparesis san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the selection of synteracthcr inc to serve as its primary contract research organization cro for its upcoming phase  clinical trial of evk evk is  html pdf add to briefcase file is in briefcase nov   evoke pharma reports third quarter  results san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced its financial results for the third quarter ended september   dave gonyer rph president and ceo stated with the net proceeds of our initial html pdf add to briefcase file is in briefcase nov   evoke pharma schedules webcast and conference call for third quarter  financial results san diego nov   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced that it will issue its financial results for the third quarter of  on wednesday november   after the close of the market evoke will hold a co html pdf add to briefcase file is in briefcase oct   evoke pharma announces full exercise of underwriters overallotment option san diego oct   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the full exercise of the overallotment option granted to the representative of the underwriters to purchase an additional  shares of its common stock at a html pdf add to briefcase file is in briefcase sep   evoke pharma announces closing of initial public offering of  shares of common stock san diego sept   globe newswire  evoke pharma inc nasdaqevok a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the closing of its previously announced initial public offering of common stock the company sold a total of  shares of its common stock at an initial  html pdf add to briefcase file is in briefcase sep   evoke pharma announces pricing of initial public offering of  shares of common stock san diego ca september    evoke pharma inc a specialty pharmaceutical company focused on treatments for gastrointestinal gi diseases today announced the pricing of its initial public offering of  shares of its common stock at a public offering price of  per share the gross proceeds to evoke pharma from the init html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one evoke pharma inc  netdania  full quote continue to netdania sign in x visit our new mobile website next time you access netdania with your mobile device home products web applications netstation application features support downloads pricing get trial five star chartnew highlights roles purchase quotelist application features support downloads pricing get trial financechart application features support downloads pricing get trial fullquotenew chartstation application features support downloads pricing get trial news alerts application server applications xml data service application pricing get trial client api application pricing get trial server api application pricing get trial mobile applications mobile app  ios apple application mobile app  android application mobile appblackberry application feeds interbank fx feednew forex stocks charts news directory calendar support references references partners contact us contact us contact us netdania privacy policy cookie policy terms and conditions your account alert central evoke pharma inc   gmt   todays range    start trading now your capital is at risk isinusg figures  evoke pharma inc open  close  year change  year  change   week high   week low  volume  inc vol  news  evoke pharma inc  gmt these are the best waterproof bluetooth speakers you can buy source forbes world symbol evoke pharma inc  gmt scientists just discovered a material that cools roofs  homes with zero energy required source forbes world symbol evoke pharma inc  gmt capitol report where healthcare reform goes after failure to repeal and replace obamacare source marketwatch symbol evoke pharma inc  gmt net neutrality and smart pipes the game is changing for verizon wireless o and others source forbes world symbol evoke pharma inc  gmt retailpocalypse amazon prime day caused  drop in store visits by amazon app users source forbes world symbol evoke pharma inc  gmt us healthcare watch mccain topple trumps skinny repeal bill source bbc uscanada symbol evoke pharma inc  gmt here’s how much you should spend on a yoga mat and why you should always use your own source marketwatch symbol evoke pharma inc  gmt how to fix push notifications on oppo phones source forbes world symbol evoke pharma inc  gmt london markets ftse  closes sharply lower in tobaccoled stock rout source marketwatch symbol evoke pharma inc  gmt how useful are time frames in economic forecasting source forbes world symbol evoke pharma inc  gmt pokémon go fest attendees suing niantic source forbes world symbol evoke pharma inc  gmt how microsoft convinced you that a laptop was better than a desktop source forbes world symbol evoke pharma inc  gmt republicans frustrated after healthcare fiasco source bbc uscanada symbol evoke pharma inc  gmt toshiba introduces new tr solid state drive series featuring layer d flash memory source forbes world symbol evoke pharma inc  gmt why people are key to improving productivity in your business source forbes world symbol evoke pharma inc  gmt buffalo bills codyyellowstone country solar eclipse legends talent traditions   ferrets source forbes world symbol evoke pharma inc  gmt odds of rate hike just went up — and so did the canadian dollar by almost a full cent source financialposttopstories symbol evoke pharma inc  gmt  starting points for getting great ideas from your team source forbes world symbol evoke pharma inc  gmt another disaster for wells fargo troubled bank admits selling unnecessary auto insurance source forbes personal finance symbol evoke pharma inc  gmt i have mixed feelings about kumail nanjiani as a middleearth shadow of war orc source forbes world symbol evoke pharma inc sign in to receive realtime news more evoke pharma inc news five star chart financechart chartstation netstation image chart five star chart – build your favorite menu  studies for mobile and desktop imagechart fivestarchart financechart chartstation share on tweet top brokers global forex dow jonescfd    sp cfd    nasdaq cfd    dax cfd    nikkei cfd    shanghai se    ftse cfd    hong kongcfd    asx cfd    nifty     gold    ukoil    eurusd    usdjpy    gbpusd    audusd    usdcad    eurjpy    eurgbp    gbpjpy    usdchf    eurchf    nzdusd    usdollar index    more more open an account your capital is at risk top gainers name last   cytrx corporati    novan inc  c    arcbest corpora    lemaitre vascul    iradimed corpor    immunogen inc    del taco restau    liberty tripadv    cesca therapeut    omnicell inc    top losers name last   destination mat    cyberoptics cor    microstrategy i    endra life sci     meta financial     echo global log    checkcap ltd    bojangles inc u    kamada ltd  o    huron consultin    get netdania mobile available for demo  live trading view the supported brokers products markets contact us support references about us netdania does not guarantee the accuracy of data contained on this website nor do we guarantee that data is realtime data on this website may be provided from otc market sources and market makers and not necessarily from exchanges the provided price data is indicative and may not be appropriate for trading or decision making purposes netdania does not assume any responsibility for any losses incurred from the use of the provided data netdania does not endorse or promote any broker or financial service netdania is a pure technology provider offering its software with broker integration any user of netdania software must be an existing client of one of our supported brokers netdania showcases netdania technology for the purpose of demonstrating it towards brokers and other institutions looking to white label the technology on a software subscription contract no financial services are offered promoted or recommended netdania is compensated as a technology provider by its institutional clients including its integrated brokers it is the sole responsibility of any recipient employing or requesting an offering to comply with all applicable legislation or regulation affecting it persons or entities including approved brokers not belonging to the netdania group may advertise on the netdania and its group’s websites through links banners or otherwise we have not taken any steps to verify the accuracy quality or reliability of any products information or services provided by third parties that have links on our website we accordingly provide no warranties with regard to and disclaim responsibility for any such products information or services and exclude all liability in this regard to the fullest extent permitted by relevant laws and regulations if a user of the netdania group’s websites decides to act upon any such advertising such user does so entirely at its own risk netdania’s website may be accessed worldwide the information provided on its website is however only intended for use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations none of the offerings services referred to on this website are available to recipients residing in countries where the provision of such offerings would constitute a violation of mandatory applicable legislation or regulations it is the sole responsibility of any recipient employing or requesting an offering to comply with all applicable legislation or regulation high risk investment warning endusers of the netdania software that make use of the trading integration features as direct clients of integrated brokers should be aware of the level of risk carried by trading in financial markets trading foreign exchange and or other financial instruments on margin carries a high level of risk and may not be suitable for all investors the high degree of leverage can work against you as well as for you before deciding to invest you should carefully consider your investment objectives level of experience and risk appetite the possibility exists that you could sustain a loss of some or more of your initial investment and therefore you should not invest money that you cannot afford to lose you should be aware of all the risks associated with trading and seek advice from your broker and or an independent financial advisor if you have any doubts anyone opening a live trading account needs to adhere to the laws of their local country as such laws may differ from country to country netdania expressly disclaims any liability for any lost principal or profits which without limitation may arise directly or indirectly from the use of or reliance on information on our website or the use of our software with broker integration copyright    netdania creations aps kronprinsessegade  st floor dk copenhagen k denmark   cvrnr terms and conditions and privacy policy the netdania website uses cookies and by continuing below you consent to this you can find out more here continue sec filings  evoke pharma home  investor relations  sec filings evokepharma sec filings filter sec filings view all filings all filings excluding section  annual quarterly current section  proxy other year all years         sort by date descending date ascending filing descending filing ascending description descending description ascending update   sec filings date filed filing description view may   k current report html pdf xls add to briefcase file is in briefcase may   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase may    widder kenneth j html pdf xls add to briefcase file is in briefcase may    rhoads ann d html pdf xls add to briefcase file is in briefcase may    hill malcolm r html pdf xls add to briefcase file is in briefcase may    glenn scott l html pdf xls add to briefcase file is in briefcase may    brady todd c html pdf xls add to briefcase file is in briefcase may    garner cam l html pdf xls add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase mar   defaa definitive additional proxy materials html pdf add to briefcase file is in briefcase mar   def a definitive proxy statement html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   k annual report html pdf xls xbrl add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase mar    gonyer david a html pdf xls add to briefcase file is in briefcase mar    donofrio matthew j html pdf xls add to briefcase file is in briefcase mar    carlson marilyn r html pdf xls add to briefcase file is in briefcase feb    latterell patrick f html pdf xls add to briefcase file is in briefcase feb    widder kenneth j html pdf xls add to briefcase file is in briefcase feb   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase feb   k current report html pdf xls add to briefcase file is in briefcase feb   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase feb   k current report html pdf xls add to briefcase file is in briefcase feb   sc ga amended statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jan    carlson marilyn r html pdf xls add to briefcase file is in briefcase jan    donofrio matthew j html pdf xls add to briefcase file is in briefcase jan    gonyer david a html pdf xls add to briefcase file is in briefcase jan   sc ga amended statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jan   k current report html pdf xls add to briefcase file is in briefcase jan   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase nov   k current report html pdf xls add to briefcase file is in briefcase nov   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase sep   ct order confidential treatment order html pdf add to briefcase file is in briefcase sep   k current report html pdf xls add to briefcase file is in briefcase aug   k current report html pdf xls add to briefcase file is in briefcase aug   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase aug   k current report html pdf xls add to briefcase file is in briefcase aug   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase aug   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase aug   k current report html pdf xls add to briefcase file is in briefcase jul   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jul   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jul   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jul   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase jul   sc ga amended statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jul   k current report html pdf xls add to briefcase file is in briefcase jul   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase jul   k current report html pdf xls add to briefcase file is in briefcase jul   k current report html pdf xls add to briefcase file is in briefcase jun   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jun   k current report html pdf xls add to briefcase file is in briefcase may    vitullo nicole html pdf xls add to briefcase file is in briefcase may    vitullo nicole html pdf xls add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase may   s registration statement html pdf xls add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase may   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase apr    widder kenneth j html pdf xls add to briefcase file is in briefcase apr    rhoads ann d html pdf xls add to briefcase file is in briefcase apr    glenn scott l html pdf xls add to briefcase file is in briefcase apr    hill malcolm r html pdf xls add to briefcase file is in briefcase apr    brady todd c html pdf xls add to briefcase file is in briefcase apr    garner cam l html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase mar   defaa definitive additional proxy materials html pdf add to briefcase file is in briefcase mar   def a definitive proxy statement html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   k annual report html pdf xls xbrl add to briefcase file is in briefcase mar    carlson marilyn r html pdf xls add to briefcase file is in briefcase mar    gonyer david a html pdf xls add to briefcase file is in briefcase mar    donofrio matthew j html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase feb    gonyer david a html pdf xls add to briefcase file is in briefcase feb    donofrio matthew j html pdf xls add to briefcase file is in briefcase feb    carlson marilyn r html pdf xls add to briefcase file is in briefcase jan    carlson marilyn r html pdf xls add to briefcase file is in briefcase jan    donofrio matthew j html pdf xls add to briefcase file is in briefcase jan    gonyer david a html pdf xls add to briefcase file is in briefcase jan   sc ga amended statement of beneficial ownership html pdf xls add to briefcase file is in briefcase dec    shah nimesh html pdf xls add to briefcase file is in briefcase nov   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase nov   k current report html pdf xls add to briefcase file is in briefcase oct   k current report html pdf xls add to briefcase file is in briefcase sep   k current report html pdf xls add to briefcase file is in briefcase sep   k current report html pdf xls add to briefcase file is in briefcase sep    gonyer david a html pdf xls add to briefcase file is in briefcase sep    carlson marilyn r html pdf xls add to briefcase file is in briefcase aug    vitullo nicole html pdf xls add to briefcase file is in briefcase aug    vitullo nicole html pdf xls add to briefcase file is in briefcase aug   k current report html pdf xls add to briefcase file is in briefcase aug   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase aug   k current report html pdf xls add to briefcase file is in briefcase may   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase apr    widder kenneth j html pdf xls add to briefcase file is in briefcase apr    rhoads ann d html pdf xls add to briefcase file is in briefcase apr    hill malcolm r html pdf xls add to briefcase file is in briefcase apr    glenn scott l html pdf xls add to briefcase file is in briefcase apr    garner cam l html pdf xls add to briefcase file is in briefcase apr    brady todd c html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr    vitullo nicole html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase apr   k current report html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   defaa definitive additional proxy materials html pdf add to briefcase file is in briefcase mar   def a definitive proxy statement html pdf xls add to briefcase file is in briefcase mar    gonyer david a html pdf xls add to briefcase file is in briefcase mar    donofrio matthew j html pdf xls add to briefcase file is in briefcase mar    carlson marilyn r html pdf xls add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase mar   k annual report html pdf xls xbrl add to briefcase file is in briefcase mar    gonyer david a html pdf xls add to briefcase file is in briefcase mar    donofrio matthew j html pdf xls add to briefcase file is in briefcase mar    carlson marilyn r html pdf xls add to briefcase file is in briefcase feb   sc g statement of beneficial ownership html pdf add to briefcase file is in briefcase feb    gonyer david a html pdf xls add to briefcase file is in briefcase feb    gonyer david a html pdf xls add to briefcase file is in briefcase feb   k current report html pdf xls add to briefcase file is in briefcase jan   k current report html pdf xls add to briefcase file is in briefcase jan   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase nov   s registration statement html pdf xls add to briefcase file is in briefcase nov   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase sep    brady todd c html pdf xls add to briefcase file is in briefcase sep    hill malcolm r html pdf xls add to briefcase file is in briefcase sep    carlson marilyn r html pdf xls add to briefcase file is in briefcase aug   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase may    widder kenneth j html pdf xls add to briefcase file is in briefcase may    rhoads ann d html pdf xls add to briefcase file is in briefcase may    hill malcolm r html pdf xls add to briefcase file is in briefcase may    glenn scott l html pdf xls add to briefcase file is in briefcase may    garner cam l html pdf xls add to briefcase file is in briefcase may    brady todd c html pdf xls add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase may   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase may   k current report html pdf xls add to briefcase file is in briefcase apr   defaa definitive additional proxy materials html pdf add to briefcase file is in briefcase apr   def a definitive proxy statement html pdf xls add to briefcase file is in briefcase mar   k annual report html pdf xls xbrl add to briefcase file is in briefcase mar   k current report html pdf xls add to briefcase file is in briefcase feb   sc g statement of beneficial ownership html pdf add to briefcase file is in briefcase feb   k current report html pdf xls add to briefcase file is in briefcase feb   sc g statement of beneficial ownership html pdf xls add to briefcase file is in briefcase jan   k current report html pdf xls add to briefcase file is in briefcase dec    gonyer david a html pdf xls add to briefcase file is in briefcase dec    donofrio matthew j html pdf xls add to briefcase file is in briefcase dec    carlson marilyn r html pdf xls add to briefcase file is in briefcase dec    carlson marilyn r html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase dec   k current report html pdf xls add to briefcase file is in briefcase nov   q quarterly report html pdf xls xbrl add to briefcase file is in briefcase nov   k current report html pdf xls add to briefcase file is in briefcase oct   k current report html pdf xls add to briefcase file is in briefcase oct    widder kenneth j html pdf xls add to briefcase file is in briefcase oct    latterell patrick f html pdf xls add to briefcase file is in briefcase oct    glenn scott l html pdf xls add to briefcase file is in briefcase oct    garner cam l html pdf xls add to briefcase file is in briefcase oct   s registration statement html pdf xls add to briefcase file is in briefcase sep    vitullo nicole html pdf xls add to briefcase file is in briefcase sep    halak brian k html pdf xls add to briefcase file is in briefcase sep    schoemaker kathleen k html pdf xls add to briefcase file is in briefcase sep    treu jesse i html pdf xls add to briefcase file is in briefcase sep    dovey brian h html pdf xls add to briefcase file is in briefcase sep    blair james c html pdf xls add to briefcase file is in briefcase sep    domain parters vii l p html pdf xls add to briefcase file is in briefcase sep    dp vii associates lp html pdf xls add to briefcase file is in briefcase sep   k current report html pdf xls add to briefcase file is in briefcase sep    widder kenneth j html pdf xls add to briefcase file is in briefcase sep    rhoads ann d html pdf xls add to briefcase file is in briefcase sep    hill malcolm r html pdf xls add to briefcase file is in briefcase sep    glenn scott l html pdf xls add to briefcase file is in briefcase sep    garner cam l html pdf xls add to briefcase file is in briefcase sep    brady todd c html pdf xls add to briefcase file is in briefcase sep   b prospectus filed pursuant to rule  html pdf xls add to briefcase file is in briefcase sep   ct order confidential treatment order html pdf add to briefcase file is in briefcase sep    halak brian k html pdf xls add to briefcase file is in briefcase sep    vitullo nicole html pdf xls add to briefcase file is in briefcase sep    schoemaker kathleen k html pdf xls add to briefcase file is in briefcase sep    treu jesse i html pdf xls add to briefcase file is in briefcase sep    dovey brian h html pdf xls add to briefcase file is in briefcase sep    kamdar kim p html pdf xls add to briefcase file is in briefcase sep    widder kenneth j html pdf xls add to briefcase file is in briefcase sep    blair james c html pdf xls add to briefcase file is in briefcase sep    domain associates html pdf xls add to briefcase file is in briefcase sep    dp vii associates lp html pdf xls add to briefcase file is in briefcase sep    domain parters vii l p html pdf xls add to briefcase file is in briefcase sep    rhoads ann d html pdf xls add to briefcase file is in briefcase sep    latterell patrick f html pdf xls add to briefcase file is in briefcase sep    hill malcolm r html pdf xls add to briefcase file is in briefcase sep    gonyer david a html pdf xls add to briefcase file is in briefcase sep    glenn scott l html pdf xls add to briefcase file is in briefcase sep    garner cam l html pdf xls add to briefcase file is in briefcase sep    donofrio matthew j html pdf xls add to briefcase file is in briefcase sep    brady todd c html pdf xls add to briefcase file is in briefcase sep   ab registration statement html pdf xls add to briefcase file is in briefcase sep   fwp free writing prospectus  filing under securities act rules  html pdf add to briefcase file is in briefcase aug   sa registration statement html pdf xls add to briefcase file is in briefcase aug   sa registration statement html pdf xls add to briefcase file is in briefcase jul   sa registration statement html pdf xls add to briefcase file is in briefcase jun   sa registration statement html pdf xls add to briefcase file is in briefcase may   s registration statement html pdf xls add to briefcase file is in briefcase jun   d small company offering and sale of securities without registration html pdf add to briefcase file is in briefcase dec   regdexa form regdexa html mar   regdexa form regdexa html jun   regdex form regdex html page     next last   view all items  add pdf file to briefcase evoke pharma  evoke pharma what is gastroparesis gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction it occurs more frequently in individuals with diabetes but also is observed in patients with prior gastric surgery a preceding infectious illness pseudoobstruction collagen vascular disorders and anorexia nervosa according to the american motility society task force on gastroparesis the prevalence is as high as  to  of the united states population common symptoms include nausea vomiting abdominal pain bloating and early satiety the disorder can cause considerable pain and discomfort and can lead to poor nutrition impaired glycemic control and diminished quality of life according to a  study published in the american journal of gastroenterology it is estimated that hospitalization costs associated with gastroparesis exceed  billion annually learn more home evokepharma t gastroparesis symptoms unpredictable  difficult to treat undissolved drug tablets in stomach simpson se clinical toxicology  severe symptoms can cause malnutrition and require hospitalization absorption of oral medications is impaired due to delayed emptying of stomach contents vomiting further complicates effectiveness of oral medications symptoms characteristic of a disease flare nausea bloating upper abdominal pain prolonged fullness early satiety vomiting  million patients with gastroparesis symptoms  only  fda approved drug estimated b prescription market b in additional hospitalization costs in  m patients currently receive treatment underdiagnosed in part due to lack of awareness diabetes is number one known cause increasing prevalence due to growing diabetes rate  of diabetic gastroparesis patients are women   current oral treatment options lack predictable delivery motility  symptoms metoclopramide st line domperidone not fdaapproved motility erythromycin not fdaapproved symptoms odansetron promethazine nausea  vomiting ppi’s upper abdominal pain narcotics upper abdominal pain   oral treatments and inadequate response erratic absorption of oral drugs significant delay dose dumping or no absorption due to vomiting unpredictable efficacy and potential safety concerns lack of compliance due to nausea and other gastroparesis symptoms  gastroparesis clinical evaluation of drugs for treatment fda guidance for industry july  gimotitm provides predictable absorption and symptom relief during a flare regardless of gastric emptying delays and vomiting email alerts  evoke pharma home  investor relations  email alerts evokepharma email alerts step  of  select options you may automatically receive evoke pharma financial information by email please enter your preferences for email notifications below and click continue to enter your contact information on the next page if you have already signed up and would like to review your subscription click here press releases press releases general releases sec filings sec filings all sec filings insider transactions quarterly and annual reports events  presentations events  presentations all events  presentations remind me choose a time  hour  hour  hours  hours  hours  day  days  days  week in advance of any event stock information stock information send me the closing stock price quote by email stock information send me a stock update at the end of the week weekly stock summary stock information alert me when the stock crosses the following price thresholds stock threshold alert low high current price  stock information alert me when the stock changes a specific percentage in one day percent change alert  in one day continue unsubscribe from investor relations email alerts our email alerts provide automated optout methods as well as complete contact information stock information  evoke pharma home  investor relations  stock information evokepharma stock information stock quote evok      pm et on jul   previous close  open  volume  exchange nasdaq day high  day low  week high  week low  stock chart stock chart benchmark benchmark nasdaq nyse sp  amex compare area graph ohlc line graph candlestick time intraday  day  month  month  months  year  years  years  years range update from to the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by edgar online both third party services and evoke pharma does not maintain or provide information directly to this service stock information is delayed approximately  minutes sign up for email alerts the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by nasdaq omx both third party services and evoke pharma does not maintain or provide information directly to this service stock information is delayed approximately  minutes evoke pharma inc  evok  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  generic drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for evok all zacks’ analyst reports premium research for evok zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores d value  a growth  b momentum  c vgm earnings esp  research report for evok snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank evoke pharma inc evok aspen pharmacr apnhy acura pharmaceuticals inc acur adamas pharmaceuticals inc adms akorn inc akrx allergan plc agn amphastar pharmaceuticals inc amph see all medical  generic drugs peers zacks news for evok evoke diabetic gastroparesis drug gimoti positive in phase iii am est zacks company news for december   am est zacks evok what are zacks experts saying now zacks private portfolio services  healthcare stocks poised to beat q earnings am est zacks company summary evoke pharma inc is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases the companys lead product candidate evk is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis evoke pharma inc is based in san diego california